The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years

Research output: Chapter in Book/Report/Conference proceedingPaper in conference proceeding

Standard

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years. / Brown, Darron R.; Kjaer, Susanne K.; Sigurdsson, Kristjan; Iversen, Ole-Erik; Hernandez-Avila, Mauricio; Wheeler, Cosette M.; Perez, Gonzalo; Koutsky, Laura A.; Tay, Eng Hseon; Garcia, Patricia; Ault, Kevin A.; Garland, Suzanne M.; Leodolter, Sepp; Olsson, Sven-Eric; Tang, Grace W. K.; Ferris, Daron G.; Paavonen, Jorma; Steben, Marc; Bosch, F. Xavier; Dillner, Joakim; Joura, Elmar A.; Kurman, Robert J.; Majewski, Slawomir; Munoz, Nubia; Myers, Evan R.; Villa, Luisa L.; Taddeo, Frank J.; Roberts, Christine; Tadesse, Amha; Bryan, Janine; Lupinacci, Lisa C.; Giacoletti, Katherine E. D.; Sings, Heather L.; James, Margaret; Hesley, Teresa M.; Barra, Eliav.

Journal Of Infectious Diseases. Vol. 199 University of Chicago Press, 2009. p. 926-935.

Research output: Chapter in Book/Report/Conference proceedingPaper in conference proceeding

Harvard

Brown, DR, Kjaer, SK, Sigurdsson, K, Iversen, O-E, Hernandez-Avila, M, Wheeler, CM, Perez, G, Koutsky, LA, Tay, EH, Garcia, P, Ault, KA, Garland, SM, Leodolter, S, Olsson, S-E, Tang, GWK, Ferris, DG, Paavonen, J, Steben, M, Bosch, FX, Dillner, J, Joura, EA, Kurman, RJ, Majewski, S, Munoz, N, Myers, ER, Villa, LL, Taddeo, FJ, Roberts, C, Tadesse, A, Bryan, J, Lupinacci, LC, Giacoletti, KED, Sings, HL, James, M, Hesley, TM & Barra, E 2009, The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years. in Journal Of Infectious Diseases. vol. 199, University of Chicago Press, pp. 926-935, 24th International Papillomavirus Conference and Clinical Workshop, 2007/11/03. https://doi.org/10.1086/597307

APA

Brown, D. R., Kjaer, S. K., Sigurdsson, K., Iversen, O-E., Hernandez-Avila, M., Wheeler, C. M., ... Barra, E. (2009). The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years. In Journal Of Infectious Diseases (Vol. 199, pp. 926-935). University of Chicago Press. https://doi.org/10.1086/597307

CBE

Brown DR, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson S-E, Tang GWK, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KED, Sings HL, James M, Hesley TM, Barra E. 2009. The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years. In Journal Of Infectious Diseases. University of Chicago Press. pp. 926-935. https://doi.org/10.1086/597307

MLA

Vancouver

Brown DR, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM et al. The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years. In Journal Of Infectious Diseases. Vol. 199. University of Chicago Press. 2009. p. 926-935 https://doi.org/10.1086/597307

Author

Brown, Darron R. ; Kjaer, Susanne K. ; Sigurdsson, Kristjan ; Iversen, Ole-Erik ; Hernandez-Avila, Mauricio ; Wheeler, Cosette M. ; Perez, Gonzalo ; Koutsky, Laura A. ; Tay, Eng Hseon ; Garcia, Patricia ; Ault, Kevin A. ; Garland, Suzanne M. ; Leodolter, Sepp ; Olsson, Sven-Eric ; Tang, Grace W. K. ; Ferris, Daron G. ; Paavonen, Jorma ; Steben, Marc ; Bosch, F. Xavier ; Dillner, Joakim ; Joura, Elmar A. ; Kurman, Robert J. ; Majewski, Slawomir ; Munoz, Nubia ; Myers, Evan R. ; Villa, Luisa L. ; Taddeo, Frank J. ; Roberts, Christine ; Tadesse, Amha ; Bryan, Janine ; Lupinacci, Lisa C. ; Giacoletti, Katherine E. D. ; Sings, Heather L. ; James, Margaret ; Hesley, Teresa M. ; Barra, Eliav. / The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years. Journal Of Infectious Diseases. Vol. 199 University of Chicago Press, 2009. pp. 926-935

RIS

TY - GEN

T1 - The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years

AU - Brown, Darron R.

AU - Kjaer, Susanne K.

AU - Sigurdsson, Kristjan

AU - Iversen, Ole-Erik

AU - Hernandez-Avila, Mauricio

AU - Wheeler, Cosette M.

AU - Perez, Gonzalo

AU - Koutsky, Laura A.

AU - Tay, Eng Hseon

AU - Garcia, Patricia

AU - Ault, Kevin A.

AU - Garland, Suzanne M.

AU - Leodolter, Sepp

AU - Olsson, Sven-Eric

AU - Tang, Grace W. K.

AU - Ferris, Daron G.

AU - Paavonen, Jorma

AU - Steben, Marc

AU - Bosch, F. Xavier

AU - Dillner, Joakim

AU - Joura, Elmar A.

AU - Kurman, Robert J.

AU - Majewski, Slawomir

AU - Munoz, Nubia

AU - Myers, Evan R.

AU - Villa, Luisa L.

AU - Taddeo, Frank J.

AU - Roberts, Christine

AU - Tadesse, Amha

AU - Bryan, Janine

AU - Lupinacci, Lisa C.

AU - Giacoletti, Katherine E. D.

AU - Sings, Heather L.

AU - James, Margaret

AU - Hesley, Teresa M.

AU - Barra, Eliav

PY - 2009

Y1 - 2009

N2 - Background. Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated. Methods. We enrolled 17,622 women aged 16-26 years. All underwent cervicovaginal sampling and Pap testing at regular intervals for up to 4 years. HPV genotying was performed for biopsy samples, and histological diagnoses were determined by a pathology panel. Analyses were conducted among subjects who were negative for 14 HPV types on day 1. Prespecified analyses included infection of >= 6 months' duration and CIN1-3/AIS due to the 2 and 5 most common HPV types in cervical cancer after HPV types 16 and 18, as well as all tested nonvaccine types. Results. Vaccination reduced the incidence of HPV-31/45 infection by 40.3% (95% confidence interval [CI], 13.9% to 59.0%) and of CIN1-3/AIS by 43.6% (95% CI, 12.9% to 64.1%), respectively. The reduction in HPV-31/33/45/52/58 infection and CIN1-3/AIS was 25.0% (95% CI, 5.0% to 40.9%) and 29.2% (95% CI, 8.3% to 45.5%), respectively. Efficacy for CIN2-3/AIS associated with the 10 nonvaccine HPV types was 32.5% (95% CI, 6.0% to 51.9%). Reductions were most notable for HPV-31. Conclusions. HPV-6/11/16/18 vaccine reduced the risk of CIN2-3/AIS associated with nonvaccine types responsible for similar to 20% of cervical cancers. The clinical benefit of cross-protection is not expected to be fully additive to the efficacy already observed against HPV-6/11/16/18-related disease, because women may have >1 CIN lesion, each associated with a different HPV type.

AB - Background. Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated. Methods. We enrolled 17,622 women aged 16-26 years. All underwent cervicovaginal sampling and Pap testing at regular intervals for up to 4 years. HPV genotying was performed for biopsy samples, and histological diagnoses were determined by a pathology panel. Analyses were conducted among subjects who were negative for 14 HPV types on day 1. Prespecified analyses included infection of >= 6 months' duration and CIN1-3/AIS due to the 2 and 5 most common HPV types in cervical cancer after HPV types 16 and 18, as well as all tested nonvaccine types. Results. Vaccination reduced the incidence of HPV-31/45 infection by 40.3% (95% confidence interval [CI], 13.9% to 59.0%) and of CIN1-3/AIS by 43.6% (95% CI, 12.9% to 64.1%), respectively. The reduction in HPV-31/33/45/52/58 infection and CIN1-3/AIS was 25.0% (95% CI, 5.0% to 40.9%) and 29.2% (95% CI, 8.3% to 45.5%), respectively. Efficacy for CIN2-3/AIS associated with the 10 nonvaccine HPV types was 32.5% (95% CI, 6.0% to 51.9%). Reductions were most notable for HPV-31. Conclusions. HPV-6/11/16/18 vaccine reduced the risk of CIN2-3/AIS associated with nonvaccine types responsible for similar to 20% of cervical cancers. The clinical benefit of cross-protection is not expected to be fully additive to the efficacy already observed against HPV-6/11/16/18-related disease, because women may have >1 CIN lesion, each associated with a different HPV type.

U2 - 10.1086/597307

DO - 10.1086/597307

M3 - Paper in conference proceeding

VL - 199

SP - 926

EP - 935

BT - Journal Of Infectious Diseases

PB - University of Chicago Press

ER -